X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3662) 3662
Book Review (701) 701
Publication (230) 230
Book Chapter (17) 17
Newsletter (11) 11
Conference Proceeding (7) 7
Web Resource (5) 5
Magazine Article (4) 4
Book / eBook (3) 3
Dissertation (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3182) 3182
humans (2916) 2916
ticlopidine - analogs & derivatives (2649) 2649
male (1777) 1777
clopidogrel (1597) 1597
ticlopidine - pharmacology (1572) 1572
female (1401) 1401
platelet aggregation inhibitors - pharmacology (1348) 1348
ticlopidine - therapeutic use (1347) 1347
platelet aggregation inhibitors - therapeutic use (1243) 1243
middle aged (1155) 1155
pharmacology & pharmacy (1123) 1123
aged (1051) 1051
aspirin (1012) 1012
platelet aggregation - drug effects (933) 933
ticlopidine (777) 777
ticlopidine - administration & dosage (676) 676
aspirin - therapeutic use (632) 632
animals (613) 613
adult (580) 580
platelet aggregation inhibitors - administration & dosage (558) 558
cardiac & cardiovascular systems (554) 554
ticlopidine - adverse effects (552) 552
percutaneous coronary intervention (551) 551
blood platelets - drug effects (547) 547
hematology (543) 543
aspirin - pharmacology (527) 527
platelet aggregation inhibitors - adverse effects (519) 519
peripheral vascular disease (488) 488
treatment outcome (473) 473
drug therapy, combination (459) 459
abridged index medicus (423) 423
antiplatelet therapy (415) 415
drug interactions (391) 391
acute coronary syndromes (367) 367
myocardial-infarction (351) 351
risk factors (346) 346
thrombosis (332) 332
ticlopidine - pharmacokinetics (323) 323
aspirin - administration & dosage (311) 311
aggregation (309) 309
stents (309) 309
platelets (303) 303
therapy (296) 296
platelet aggregation inhibitors - pharmacokinetics (288) 288
prasugrel (285) 285
time factors (284) 284
drug therapy (282) 282
blood platelets (279) 279
risk (269) 269
adenosine diphosphate - pharmacology (266) 266
platelet aggregation (263) 263
acute coronary syndrome - drug therapy (260) 260
inhibition (258) 258
rats (258) 258
dose-response relationship, drug (251) 251
prospective studies (250) 250
blood platelets - metabolism (245) 245
genotype (244) 244
aged, 80 and over (240) 240
medicine & public health (240) 240
platelet activation - drug effects (239) 239
stroke (238) 238
platelet function tests (236) 236
prevention (222) 222
cardiology (221) 221
drug resistance (220) 220
thiophenes - pharmacology (218) 218
cytochrome p-450 cyp2c19 (217) 217
pharmacokinetics (215) 215
trial (213) 213
prasugrel hydrochloride (212) 212
analysis (208) 208
coronary heart disease (207) 207
acute myocardial-infarction (203) 203
platelet reactivity (203) 203
adenosine - analogs & derivatives (199) 199
cardiac patients (197) 197
thrombosis - prevention & control (196) 196
cardiovascular disease (195) 195
aryl hydrocarbon hydroxylases - genetics (193) 193
pharmacology (193) 193
angioplasty, balloon, coronary (192) 192
aspirin - adverse effects (192) 192
stent thrombosis (189) 189
research (188) 188
care and treatment (187) 187
resistance (182) 182
cardiovascular diseases (177) 177
polymorphism, genetic (174) 174
dosage and administration (173) 173
heart attacks (173) 173
coronary artery disease - drug therapy (172) 172
acute coronary syndrome (171) 171
cardiovascular events (167) 167
intervention (167) 167
myocardial infarction - drug therapy (165) 165
artery-disease (162) 162
pharmacology/toxicology (161) 161
cardiovascular (158) 158
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3485) 3485
French (35) 35
German (34) 34
Japanese (31) 31
Chinese (28) 28
Russian (28) 28
Spanish (17) 17
Italian (12) 12
Polish (6) 6
Dutch (4) 4
Danish (2) 2
Finnish (2) 2
Hungarian (2) 2
Portuguese (2) 2
Turkish (2) 2
Czech (1) 1
Hebrew (1) 1
Norwegian (1) 1
Romanian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 92 - 99
The aim of the current study is to identify the human cytochrome P450 (P450) isoforms involved in the two oxidative steps in the bioactivation of clopidogrel... 
MECHANISM-BASED INHIBITION | ANTIAGGREGATING ACTIVITY | POLYMORPHISMS | TICLOPIDINE | PHARMACOKINETICS | HEALTHY-SUBJECTS | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS | MONOCLONAL-ANTIBODIES | ATORVASTATIN | Microsomes - metabolism | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Cytochrome P-450 Enzyme System - metabolism | Sulfaphenazole - pharmacology | Microsomes - drug effects | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Antibodies - immunology | Omeprazole - pharmacology | Microsomes, Liver - enzymology | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - immunology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Ticlopidine - analogs & derivatives | Oxidoreductases, N-Demethylating - immunology | Cytochrome P-450 CYP3A - metabolism | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Theophylline - pharmacology | Kinetics | Cytochrome P-450 CYP2C9 | Theophylline - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Glutathione - metabolism | Ketoconazole - pharmacology | Biotransformation - physiology | Cytochrome P-450 CYP1A2 Inhibitors | Microsomes, Liver - drug effects | Ticlopidine - metabolism | NADP - metabolism | Platelet Aggregation Inhibitors - metabolism | Cytochrome P-450 CYP3A - immunology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 - immunology | Biocatalysis | Mephenytoin - analogs & derivatives | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Mephenytoin - pharmacology | Antibodies - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP2C19 | Clopidogrel | Cytochrome P-450 CYP2B6 | Index Medicus
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 12/2006, Volume 46, Issue 12, pp. 1426 - 1438
Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of drugs such as bupropion, efavirenz, propofol, and selegiline, among others. More than 200... 
HPLC/MS/MS | P450 2B6 | rhCYP2B6 | Drug‐drug interactions | in vitro | Drug-drug interactions | In vitro | Raloxifene Hydrochloride - pharmacology | Cytochrome P-450 Enzyme Inhibitors | Humans | Microsomes, Liver - metabolism | Sertraline - chemistry | Bupropion - analogs & derivatives | Cytochrome P-450 Enzyme System - metabolism | Antifungal Agents - chemistry | Xenobiotics - pharmacology | Reverse Transcriptase Inhibitors - chemistry | Xenobiotics - classification | Clotrimazole - metabolism | Platelet Aggregation Inhibitors - pharmacology | Oxazines - pharmacology | Antifungal Agents - pharmacology | Itraconazole - metabolism | Serotonin Uptake Inhibitors - metabolism | Clotrimazole - pharmacology | Serotonin Uptake Inhibitors - chemistry | Antidepressive Agents, Second-Generation - pharmacology | Clotrimazole - chemistry | Itraconazole - chemistry | Selective Estrogen Receptor Modulators - metabolism | Ticlopidine - analogs & derivatives | Raloxifene Hydrochloride - metabolism | Platelet Aggregation Inhibitors - chemistry | Oxazines - chemistry | Kinetics | Serotonin Uptake Inhibitors - pharmacology | Selective Estrogen Receptor Modulators - pharmacology | Bupropion - metabolism | Ticlopidine - pharmacology | Area Under Curve | Reverse Transcriptase Inhibitors - pharmacology | Ticlopidine - chemistry | Benzoxazines | Xenobiotics - pharmacokinetics | Itraconazole - pharmacology | Oxazines - metabolism | Microsomes, Liver - drug effects | Antifungal Agents - metabolism | Ticlopidine - metabolism | Molecular Structure | Platelet Aggregation Inhibitors - metabolism | Sertraline - metabolism | Sertraline - pharmacology | Selective Estrogen Receptor Modulators - chemistry | Algorithms | Bupropion - pharmacology | Reverse Transcriptase Inhibitors - metabolism | Antidepressive Agents, Second-Generation - metabolism | Raloxifene Hydrochloride - chemistry | Cytochrome P-450 CYP2B6 | Cytochromes | Research | Health aspects | Drug interactions | Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 09/2014, Volume 34, Issue 9, pp. 2078 - 2085
OBJECTIVE—In a phase III clinical trial (PLATelet inhibition and patient Outcomes, PLATO), ticagrelor provided better clinical outcomes than clopidogrel in... 
adenosine | aspirin | cyclooxygenase | platelet aggregation inhibitors | ISCHEMIA/REPERFUSION INJURY | ACUTE CORONARY SYNDROMES | PLATO | COMBINATION | ATORVASTATIN | ISCHEMIA-REPERFUSION INJURY | CLOPIDOGREL | PLATELET INHIBITION | PERIPHERAL VASCULAR DISEASE | CARDIOPROTECTION | HEMATOLOGY | Receptor, Adenosine A1 - physiology | Ticlopidine - therapeutic use | Nitric Oxide Synthase Type III - biosynthesis | Adenosine A1 Receptor Antagonists - pharmacology | Male | Receptor, Adenosine A2A - physiology | Cardiotonic Agents - therapeutic use | Cyclooxygenase 2 - biosynthesis | Myocardial Reperfusion Injury - pathology | Cyclooxygenase 2 - genetics | Adenosine - therapeutic use | Myocardial Infarction - pathology | Enzyme Induction - drug effects | Nitric Oxide Synthase Type III - physiology | Aspirin - pharmacology | Myocardial Reperfusion Injury - drug therapy | Drug Evaluation, Preclinical | Pyrazoles - pharmacology | Cyclooxygenase 2 Inhibitors - pharmacology | Rats | Cyclooxygenase 2 - physiology | Adenosine - pharmacology | Cardiotonic Agents - pharmacology | Nitric Oxide Synthase Type III - genetics | Rats, Sprague-Dawley | Ticlopidine - analogs & derivatives | Triazoles - pharmacology | Up-Regulation - drug effects | Adenosine A2 Receptor Antagonists - pharmacology | Animals | Myocardial Infarction - drug therapy | Adenosine - analogs & derivatives | Adenosine - physiology | 6-Ketoprostaglandin F1 alpha - metabolism | Quinazolines - pharmacology | Lipoxins - metabolism | Myocardial Reperfusion Injury - prevention & control | Index Medicus
Journal Article
Journal Article
Journal Article
Molecules, ISSN 1420-3049, 01/2017, Volume 22, Issue 1, pp. 114 - 114
The potential role of non-antibiotic medicinal products in the treatment of multidrug-resistant Gram-negative bacteria has recently been investigated. It is... 
Drugs | Efflux | Efflux pump inhibitor | MDR | Non-antibiotics | Gram-negative bacteria | Medicinal products | PA βN | Quinolones | medicinal products | INFECTIONS | non-antibiotics | drugs | ESCHERICHIA-COLI | CHEMISTRY, ORGANIC | PREVALENCE | efflux | ACINETOBACTER-BAUMANNII | efflux pump inhibitor | ANTIBACTERIAL ACTIVITY | PSEUDOMONAS-AERUGINOSA | quinolones | ARG-BETA-NAPHTHYLAMIDE | DRUG EFFLUX | PAN | MULTIDRUG-RESISTANCE | ANTIMICROBIAL ACTIVITY | Klebsiella pneumoniae - drug effects | Magnesium Sulfate - pharmacology | Ticlopidine - pharmacology | Atorvastatin Calcium - pharmacology | Escherichia coli - drug effects | Pseudomonas aeruginosa - growth & development | Quinolones - pharmacology | Nicergoline - pharmacology | Microbial Sensitivity Tests | Pseudomonas aeruginosa - metabolism | Escherichia coli - metabolism | Escherichia coli - growth & development | Genes, MDR - drug effects | Klebsiella pneumoniae - metabolism | Salmonella - metabolism | Dipeptides - pharmacology | Acyclovir - pharmacology | Salmonella - drug effects | Pseudomonas aeruginosa - drug effects | Alendronate - pharmacology | Klebsiella pneumoniae - growth & development | Salmonella - growth & development | Anti-Bacterial Agents - pharmacology | Famotidine - pharmacology | Amitriptyline - pharmacology | Drug Resistance, Multiple, Bacterial - genetics | Drug Resistance, Multiple, Bacterial - drug effects | Drug Combinations | Antibiotics | Multidrug resistance | Index Medicus | PAβN
Journal Article
Molecules, ISSN 1420-3049, 2018, Volume 23, Issue 3, p. 555
Sauchinone, an active lignan isolated from the aerial parts of Saururus chinensis (Saururaceae), exhibits anti-inflammatory, anti-obesity, anti-hyperglycemic,... 
Saururus chinensis | Herb-drug interaction | CYP450 | Metabolic inhibition | Sauchinone | Human liver microsome | Docking | sauchinone | BIOCHEMISTRY & MOLECULAR BIOLOGY | herb-drug interaction | INTERACTIONS FOCUS | PRESCRIBED DRUGS | HERBAL MEDICINES | CHEMISTRY, MULTIDISCIPLINARY | docking | IN-VITRO | INHIBITION | PHARMACOKINETICS | STRUCTURAL BASIS | human liver microsome | METABOLIC ENZYMES | BINDING | DRUG-DRUG INTERACTIONS | metabolic inhibition | Plant Extracts - pharmacology | Humans | Chlorzoxazone - chemistry | Benzopyrans - chemistry | Cytochrome P-450 CYP3A - chemistry | Dioxoles - pharmacology | Anti-Inflammatory Agents - isolation & purification | Cytochrome P-450 Enzyme Inhibitors - chemistry | Microsomes, Liver - enzymology | Binding Sites | Anti-Inflammatory Agents - pharmacology | Plant Extracts - isolation & purification | Saururaceae - chemistry | Benzopyrans - isolation & purification | Microsomes, Liver - chemistry | Dioxoles - chemistry | Ticlopidine - analogs & derivatives | Hypoglycemic Agents - pharmacology | Hypoglycemic Agents - isolation & purification | Anti-Obesity Agents - chemistry | Cytochrome P-450 CYP3A - metabolism | Mice | Molecular Docking Simulation | Kinetics | Anti-Obesity Agents - pharmacology | Cytochrome P-450 CYP2B6 - chemistry | Cytochrome P-450 Enzyme Inhibitors - isolation & purification | Plant Extracts - chemistry | Ticlopidine - pharmacology | Ticlopidine - chemistry | Cytochrome P-450 CYP2E1 - metabolism | Cytochrome P-450 CYP2B6 - metabolism | Microsomes, Liver - drug effects | Cyclobutanes - pharmacology | Protein Interaction Domains and Motifs | Benzopyrans - pharmacology | Cytochrome P-450 CYP2E1 - chemistry | Catalytic Domain | Dioxoles - isolation & purification | Protein Structure, Secondary | Plant Components, Aerial - chemistry | Cytochrome P-450 CYP2C19 - chemistry | Hypoglycemic Agents - chemistry | Anti-Obesity Agents - isolation & purification | Cytochrome P-450 Enzyme Inhibitors - pharmacology | Animals | Anti-Inflammatory Agents - chemistry | Chlorzoxazone - pharmacology | Herb-Drug Interactions | Protein Binding | Clopidogrel | Cytochrome P-450 CYP2C19 - metabolism | Cyclobutanes - chemistry | Cytochrome | Herbs | Drugs | Liver | Drug interactions | Amino acids | Inflammation | Sibutramine | Metabolism | Microsomes | Steatosis | Chlorzoxazone | Fatty liver | Mouse devices | Computer applications | Cytochromes | In vivo methods and tests | Drug interaction | Inhibition | Enzyme kinetics | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2012, Volume 60, Issue 3, pp. 193 - 199
Journal Article
Circulation, ISSN 0009-7322, 09/2004, Volume 110, Issue 11, pp. 1392 - 1397
Background-Platelet activation is a hallmark of acute coronary syndromes. Numerous lines of evidence suggest a mechanistic link between von Willebrand factor... 
Myocardial infarction | Platelets | Creatine kinase | Collagen | CARDIAC & CARDIOVASCULAR SYSTEMS | FUNCTION ANALYZER PFA-100 | myocardial infarction | collagen | AMERICAN-COLLEGE | ACUTE CORONARY SYNDROMES | platelets | PRACTICE GUIDELINES COMMITTEE | ADHESION | VONWILLEBRAND-FACTOR | ASSOCIATION TASK-FORCE | PERIPHERAL VASCULAR DISEASE | creatine kinase | UNSTABLE ANGINA | DYSFUNCTION | INTERVENTION | Tyrosine - pharmacology | Myocardial Infarction - blood | Predictive Value of Tests | Prospective Studies | Ticlopidine - pharmacology | Ticlopidine - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Tyrosine - analogs & derivatives | Necrosis | Tyrosine - therapeutic use | Myocardial Infarction - pathology | Female | Aspirin - therapeutic use | Collagen - pharmacology | Leukocyte Count | Aspirin - pharmacology | Platelet Aggregation Inhibitors - therapeutic use | von Willebrand Factor - analysis | Comorbidity | Antibodies, Monoclonal - pharmacology | Myocardial Ischemia - blood | Anticoagulants - therapeutic use | Myocardium - pathology | Immunoglobulin Fab Fragments - pharmacology | Ticlopidine - analogs & derivatives | Adenosine Diphosphate - pharmacology | Myocardial Ischemia - pathology | Peptides - pharmacology | Cardiovascular Agents - therapeutic use | Platelet Function Tests - instrumentation | Aged | Platelet Activation - drug effects | Peptides - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
European Heart Journal, ISSN 0195-668X, 09/2012, Volume 33, Issue 17, pp. 2151 - 2162
Aims CYP3A4-metabolized statins can influence the pharmacodynamic effect of clopidogrel. We sought to assess the impact of switching to a... 
Atorvastatin | Clopidogrel | Platelet | Non-CYP3A4-metabolized statin | High platelet reactivity | REDUCTASE INHIBITORS | CARDIAC & CARDIOVASCULAR SYSTEMS | ABCB1 | GENETIC-VARIANTS | CYP2C19 | CYTOCHROME-P450 3A4 | CLINICAL PHARMACOGENETICS | DRUG-DRUG INTERACTION | TRIAL | PERCUTANEOUS CORONARY INTERVENTION | Prospective Studies | Ticlopidine - therapeutic use | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Cytochrome P-450 CYP3A - physiology | Male | Pyrimidines - metabolism | Fluorobenzenes - pharmacology | Cytochrome P-450 CYP3A - genetics | Platelet Aggregation Inhibitors - pharmacology | Female | Aspirin - therapeutic use | Platelet Aggregation - drug effects | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Fluorobenzenes - metabolism | Pravastatin - metabolism | Rosuvastatin Calcium | Genotype | Coronary Artery Disease - drug therapy | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Ticlopidine - analogs & derivatives | Adenosine Diphosphate - pharmacology | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Sulfonamides - metabolism | Drug Substitution | Fluorobenzenes - therapeutic use | Percutaneous Coronary Intervention | Index Medicus
Journal Article
Catheterization and Cardiovascular Interventions, ISSN 1522-1946, 06/2018, Volume 91, Issue 7, pp. 1318 - 1319
In patients with peripheral artery disease, high on‐treatment platelet reactivity (HoTPR) might be associated with worse outcomes for those taking clopidogrel,... 
CARDIAC & CARDIOVASCULAR SYSTEMS | Clopidogrel | Aspirin | Peripheral Arterial Disease | Humans | Platelet Aggregation Inhibitors | Ticlopidine | Genes | Vascular diseases | Medical treatment | Reimbursement | Pharmacology | Patients | Index Medicus
Journal Article
Journal Article